IPO - FEMASYS INC
Form Type: 424B5
Filing Date: 2025-05-29
Corporate Action: Ipo
Type: New
Accession Number: 000114036125020782
Filing Summary: Femasys Inc. is offering shares of common stock at a purchase price to be determined. The common stock is listed on the Nasdaq Capital Market under the symbol 'FEMY.' The last reported sale price on May 28, 2025, was $1.06 per share. This offering includes underwriting discounts of 7% on gross proceeds. A concurrent private placement is anticipated with institutional stockholders and certain company officers purchasing shares at the same public offering price. The offering is not contingent on the private placement and vice versa. Femasys is noted for its innovative products in women's health, specifically its FemBloc permanent birth control system, which has received regulatory approvals and is being commercialized in both U.S. and international markets. The company recently experienced Nasdaq notice for minimum listing requirements but continues to monitor its situation until November 2025. New equity lines may also be established to secure additional funding. There is a caution regarding forward-looking statements within the prospectus.
Additional details:
Total Public Offering Price:
Underwriting Discounts And Commissions:
Proceeds To Us Before Expenses:
Market Value Of Outstanding Common Stock: 33000000
Number Of Outstanding Shares: 25551370
Closing Price Of Common Stock On April 2 2025: 1.29
Private Placement Interest: Certain existing institutional stockholders and certain of our directors and officers have indicated an interest in the Concurrent Private Placement.
Concurrent Private Placement Close: Expected to close concurrently with this offering.
Placement Agent Fee: 7
Equity Line Of Credit: Expected to enter into a $10 million equity line of credit with Alumni Capital LP by June 30, 2025.
Nasdaq Delisting Notice Received: May 19, 2025
Deadline To Regain Compliance: November 17, 2025
Comments
No comments yet. Be the first to comment!